Aurora kinase inhibitors: Progress towards the clinic

0377543 - ÚOCHB 2013 RIV US eng J - Journal Article
Kollareddy, M. - Zheleva, D. - Dzubak, P. - Brahmkshatriya, Pathik - Lepšík, Martin - Hajduch, M.
Aurora kinase inhibitors: Progress towards the clinic.
Investigational New Drugs. Roč. 30, č. 6 (2012), s. 2411-2432. ISSN 0167-6997. E-ISSN 1573-0646
Grant - others:GA ČR(CZ) GA301/08/1649; GA ČR(CZ) GD303/09/H048
Program: GA; GD
Institutional research plan: CEZ:AV0Z40550506
Keywords : Aurora kinases * cancer * inhibitors
Subject RIV: CF - Physical ; Theoretical Chemistry
Impact factor: 3.498, year: 2012

The Aurora kinases (serine/threonine kinases) were discovered in 1995 during studies of mutant alleles associated with abnormal spindle pole formation in Drosophila melanogaster. They soon became the focus of much attention because of their importance in human biology and association with cancer. Aurora kinases are essential for cell division and are primarily active during mitosis. Following their identification as potential targets for cancer chemotherapy, many Aurora kinase inhibitors have been discovered and developed. Currently, there are about 30 Aurora kinase inhibitors in different stages of pre-clinical and clinical development. This review summarizes the characteristics and status of Aurora kinase inhibitors in preclinical, Phase I, and Phase II clinical studies, with particular emphasis on the mechanisms of action and resistance to these promising anticancer agents.
Permanent Link: http://hdl.handle.net/11104/0209672